Torrent Pharmaceuticals Enters into Non-Exclusive Patent Licensing Agreement with Takeda Pharmaceuticals to Commercialize its Novel Gastrointestinal Drug in India

Torrent Pharmaceuticals Limited (Torrent) today announced that it has entered into a non-exclusive patent licensing agreement with Takeda to commercialize Vonoprazan in India. Vonoprozan is a novel potassium-competitive acid blocker (P-CAB), used for the treatment of acid related disorders - Gastroesophageal Reflux Disease (GERD). Torrent will market Vonoprazan under its own trademark, Kabvie.

As per a 2019 study published by Indian Journal of Gastroenterology prevalence of GERD in Indian population is around 8.2%, with a higher prevalence of around 11.1% in urban population. According to AWACS MAT April 2024 data, the Indian market for treatments used in GERD is valued at INR 8,064 crore, growing at 8% CAGR over the last 4 years. Currently treatments such as Pantoprazole (Proton Pump Inhibitors) are used to treat GERD. Availability of P-CABs such as Kabvie will make accessible new and effective treatments of GERD for the Indian population.

Commenting on the agreement, Aman Mehta - Director, Torrent said, "We are delighted to commercialize this novel treatment for Indian patients. I am confident that the launch of Kabvie will aid in reducing the disease burden of GERD and further strengthen our Gastrointestinal offerings, augmenting our position as a leading player within the Indian Pharmaceutical Market."

Shares of Torrent Pharmaceuticals Limited was last trading in BSE at Rs. 2780.05 as compared to the previous close of Rs. 2697.05. The total number of shares traded during the day was 13681 in over 2285 trades.

The stock hit an intraday high of Rs. 2800.00 and intraday low of 2688.00. The net turnover during the day was Rs. 37758584.00.

Source : Equity Bulls

Keywords

TorrentPharmaceuticals INE685A01028 PatentLicensingAgreement NonExclusive Takeda Vonoprazan India